Dr. Meena flags five weight‑loss drug mistakes
- Chicago physician Meena T. Malhotra said patients on Wegovy- and Ozempic-like drugs often undermine treatment by skipping medical oversight, nutrition, and exercise basics. - Her five pitfalls include rushing dose increases, ignoring protein and hydration, avoiding strength training, and treating the drugs as a stand-alone fix. - The backdrop is broader GLP-1 use and safety scrutiny, with FDA warning about unapproved compounded versions and proper supervision. (fda.gov)
Weight-loss drugs like Wegovy and Ozempic are not designed to work alone, Chicago physician Meena T. Malhotra said in outlining five common patient mistakes. (aol.com) Malhotra, a Glenview, Illinois, physician whose practice says she is board certified in obesity and internal medicine, said some patients start these drugs without a full medical plan. She said others raise doses too fast, which can worsen nausea, vomiting, constipation, and other stomach side effects. (drmeena.com) (aol.com) (wegovy.com) The Wegovy prescribing information tells patients to follow a stepped dose-escalation schedule, and says restarting after missed doses may require going back through escalation to reduce gastrointestinal symptoms. Wegovy is also labeled for use with a reduced-calorie diet and increased physical activity, not as a substitute for them. (accessdata.fda.gov) (novo-pi.com) Another mistake Malhotra flagged is under-eating protein and neglecting hydration while appetite is suppressed. She also pointed to muscle loss risk when patients lose weight without resistance training or enough food quality. (aol.com) (sciencedirect.com) To understand the diet piece, start with what these medicines copy. Glucagon-like peptide-1, or GLP-1, is a gut hormone that helps control blood sugar, slows stomach emptying, and signals fullness to the brain. (theconversation.com) University of Washington gastroenterologist Christopher Damman wrote that lower-gut bacteria turn fiber and polyphenols from plant foods into molecules that stimulate GLP-1 and related hormones such as peptide YY. He argues that heavily processed diets strip out many of the food components that help that system run. (theconversation.com) That does not mean food can replace prescription treatment for everyone. The National Institute of Diabetes and Digestive and Kidney Diseases says obesity is a chronic disease affecting more than 4 in 10 U.S. adults, and medications may be added when diet and activity alone are not enough. (niddk.nih.gov) The supervision warning is getting sharper as demand spreads beyond brand-name prescriptions. The Food and Drug Administration says unapproved compounded GLP-1 drugs do not undergo the agency’s premarket review for safety, effectiveness, or quality. (fda.gov) FDA also said some compounded injectable GLP-1 products have arrived warm or with inadequate ice packs, a storage problem that can affect drug quality. The agency said patients should use compounded drugs only when an approved drug cannot meet a medical need, and only with a prescription filled at a state-licensed pharmacy. (fda.gov) The practical message from the reporting is narrower than the hype around these drugs: follow the dosing schedule, keep a clinician involved, and treat protein, hydration, fiber, and strength training as part of the prescription. (aol.com) (accessdata.fda.gov)
